Supplementary Tables S1-S10 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors

Suppl. Table S1. Clinicopathologic features of new and published cases of EWSR1/FUS::POU5F1-rearranged MET Suppl. Table S2. Clinicopathologic features of new and published cases of SS18::PBX1/3-rearranged MET Suppl. Table S3. Clinicopathologic features of new and published cases of EWSR1::KLF15-rearranged MET Suppl. Table S4. Clinicopathologic features of new and published cases of EWSR1/FUS::KLF17-rearranged MET Suppl. Table S5. Clinicopathologic features of new and published cases of EWSR1::ZNF444-rearranged MET Suppl. Table S6. Clinicopathologic features of new and published cases of EWSR1::PBX1/3-rearranged MET Suppl. Table S7. Clinicopathologic features of new and published cases of PLAG1-altered MET Suppl. Table S8. Clinicopathologic summary of fusion-positive myoepithelial tumors (new and published cases) Suppl. Table S9. Significant differentially methylated regions: ENT and cutaneous PLAG1-rearranged vs FET-rearranged myoepithelial tumors Suppl. Table S10. Univariate and Multivariate Survival Analysis for Disease-specific Survival (DSS) and Progression-free Survival (PFS)